{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T07:21:25Z","timestamp":1785655285467,"version":"3.56.0"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T00:00:00Z","timestamp":1334102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer's disease (AD) symptoms across all severity stages. The ROSA and four standard instruments \u2014 the Alzheimer's disease Assessment Scale\u2010cognitive (ADAS\u2010cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) \u2014 were used in an open\u2010label, multicenter, single\u2010arm clinical study to assess treatment\u2010induced changes in cognitive, functional, and behavioral symptoms in patients with AD at different severity stages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 451 patients were treated with memantine (initiated at 5\u2009mg\/day and up\u2010titrated with 5\u2009mg weekly to a final dose of 20\u2009mg\/day) for 12\u2009weeks. The study endpoints comprised changes from baseline in the scores of the ROSA, ADAS\u2010cog, SIB, DAD, and NPI as well as global changes on the Clinical Global Impression of Change (CGI\u2010C). Analyses were performed for the overall population and by AD severity stage (early, middle, late).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The ROSA scores increased significantly after a 12\u2010week treatment in all study groups except for early stage. Mean changes in the ADAS\u2010cog score indicated a trend towards worsening in early and middle stages. Non\u2010significant changes were shown by the SIB, NPI, and DAD assessments at week 12. The CGI\u2010C demonstrated \u2018minimal improvement\u2019 or \u2018no change\u2019 for most of the patients. Overall, memantine treatment was safe and well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results demonstrated the ROSA feasibility in daily practice for assessment of memantine effects over time in patients with moderate and late AD. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/gps.3805","type":"journal-article","created":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T15:26:55Z","timestamp":1334158015000},"page":"164-172","source":"Crossref","is-referenced-by-count":7,"title":["Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open\u2010label, single\u2010arm, multicenter clinical study"],"prefix":"10.1002","volume":"28","author":[{"given":"Vjera","family":"Holthoff","sequence":"first","affiliation":[{"name":"DZNE, German Center for Neurodegenerative Diseases Dresden, and University Hospital Carl Gustav Carus, University of Technology  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ferris","sequence":"additional","affiliation":[{"name":"Alzheimer's Disease Center New York University Langone Medical Center  New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[{"name":"McGill Centre for Studies in Aging  Verdun Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Ihl","sequence":"additional","affiliation":[{"name":"Clinic of Geriatric Psychiatry and Psychotherapy Alexian Krefeld GmbH  Krefeld Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Robert","sequence":"additional","affiliation":[{"name":"Memory Center, EA CoBTek Universit\u00e9 de Nice Sophia Antipolis  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Alzheimer Disease Research Center Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Sternberg","sequence":"additional","affiliation":[{"name":"Merz Pharmaceuticals GmbH  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tennigkeit","sequence":"additional","affiliation":[{"name":"AC Immune SA  Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The ROSA Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,11]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000223333.42368.f1"},{"issue":"9","key":"e_1_2_11_5_1","first-page":"49","article-title":"Meta\u2010analysis of 6\u2010month memantine clinical trials in Alzheimer's disease","volume":"58","author":"Doody RS","year":"2005","journal-title":"Ann Neurol"},{"key":"e_1_2_11_6_1","first-page":"89","article-title":"Mini\u2010Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein MF","year":"1975","journal-title":"J Psychiatr Res"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1341"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.53.5.471"},{"key":"e_1_2_11_9_1","first-page":"217","volume-title":"Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt8921914212"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013128"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(18)30669-4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200607000-00002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.317"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000102568"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.3805","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.3805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:05:57Z","timestamp":1698638757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.3805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,11]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1002\/gps.3805"],"URL":"https:\/\/doi.org\/10.1002\/gps.3805","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,11]]}}}